Zobrazeno 1 - 10
of 558
pro vyhledávání: '"Peter C. Taylor"'
Autor:
Peter C. Taylor, Bryan Downie, Ling Han, Rachael Hawtin, Angie Hertz, Robert J. Moots, Tsutomu Takeuchi
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1383-1392 (2024)
Abstract Introduction High baseline neutrophil-to-lymphocyte ratio (NLR) in rheumatoid arthritis (RA) has been associated with positive responses to biologic tumor necrosis factor inhibition and negative responses to conventional synthetic disease-mo
Externí odkaz:
https://doaj.org/article/8791698927c94580b5379123fd399380
Autor:
Yoshiya Tanaka, Peter C. Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A. Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 5, Pp 1335-1348 (2023)
Abstract Introduction Our aim was to evaluate protein biomarker changes related to the administration of filgotinib, a Janus kinase (JAK) 1 preferential inhibitor, in patients with moderately to severely active rheumatoid arthritis (RA) with inadequa
Externí odkaz:
https://doaj.org/article/42bef335c7494c6c9933325ae15de018
Autor:
Lars Erik Kristensen, Victoria Navarro-Compán, Marina Magrey, Andrew G. Bushmakin, Joseph C. Cappelleri, Arne Yndestad, Oluwaseyi Dina, Peter C. Taylor
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 4, Pp 1073-1087 (2023)
Abstract Introduction Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Using mediation modelling, we describe interrelationships between fatigue, pain, morning stiffness, C-reactive protein (CRP) and tofacit
Externí odkaz:
https://doaj.org/article/3c522789b45749f6a6d68b464bcbeb6a
Autor:
Peter C. Taylor, Ayman Askari, Ernest Choy, Michael R. Ehrenstein, Sara Else, Muhammad K. Nisar
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract Background Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint pain and stiffness. Biologics represent some of the most effective treatments for RA, but previous guidance from the National Institute for
Externí odkaz:
https://doaj.org/article/7b0471b44dda43c790c34ef8738fd283
Autor:
Yoshiya Tanaka, Peter C. Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A. Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 1, Pp 223-224 (2023)
Externí odkaz:
https://doaj.org/article/b25389f148c54be1a0bd1e4e87cf6c73
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 2, Pp 433-445 (2023)
Abstract Introduction The aim of this work is to compare real-world outcomes of patients with rheumatoid arthritis (RA) receiving adalimumab (ADA) bio-originator (non-switchers) to those who had switched from ADA bio-originator to an ADA biosimilar (
Externí odkaz:
https://doaj.org/article/141dad39192745bab55f40f357b036b4
Autor:
Peter C. Taylor, Yun-Fei Chen, Janet Pope, Michael Weinblatt, Eduardo Mysler, Andrea Rubbert-Roth, Bochao Jia, Luna Sun, Yushi Liu, Thorsten Holzkämper, Yoshiya Tanaka
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 2, Pp 463-476 (2023)
Plain Language Summary Baricitinib is an oral agent widely approved for the treatment of moderately to severely active rheumatoid arthritis). Although baricitinib (and other agents) have demonstrated efficacy at the population level, treatment respon
Externí odkaz:
https://doaj.org/article/db973ae12e4040fbb0269c01ccf82ada
Autor:
Janet E. Pope, Yvonne C. Lee, Jeffrey R. Curtis, Daojun Mo, Li Xie, Christina L. Dickson, Douglas E. Schlichting, Anabela Cardoso, Lee S. Simon, Peter C. Taylor
Publikováno v:
ACR Open Rheumatology, Vol 4, Iss 3, Pp 254-258 (2022)
Objective Pain reduction with baricitinib was assessed in patients with rheumatoid arthritis (RA) who either used opioids or did not use opioids during three randomized, double‐blind phase 3 trials. Methods Analysis populations were as follows: i)
Externí odkaz:
https://doaj.org/article/86a87bdaa02641a29f900d98f08520ca
Autor:
Bruno Fautrel, Rieke Alten, Yves Piette, Roberto Caporali, Susana Romero-Yuste, Jasper Broen, Katrien Van Beneden, Martin Welcker, Peter C. Taylor, Oliver Howell, Elke Rottier, Monia Zignani
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Background While treat-to-target (T2T) is endorsed for the management of rheumatoid arthritis (RA), data on the degree of implementation in clinical practice are limited. This study investigated the use of T2T for RA in a real-world setting across Eu
Externí odkaz:
https://doaj.org/article/822b21dea1ea4f8f9e6bb9c678a2f607
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 14 (2022)
Anti-tumour necrosis factors (anti-TNFs) are established as first-line biological therapy for rheumatoid arthritis (RA) with over two decades of accumulated clinical experience. Anti-TNFs have well established efficacy/safety profiles along with addi
Externí odkaz:
https://doaj.org/article/be095710da1541dfb976f84d2d51e9da